RayKnowChina Research Map
Shortlist0

Not yet recruitingAplastic anaemiaPhase 2

Registered title, quoted from ClinicalTrials.gov

Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT

An open trial on aplastic anaemia, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of USTC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07885982, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 1 year to 50 years; sex: all

    Registered eligibility fields

  2. Serum ferritin <1000 μg/L, or prior iron chelation therapy if serum ferritin exceeds this threshold.

    Inclusion criterion 9

    Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during treatment and for 12 months after transplantation.

    Inclusion criterion 10

  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

    Inclusion criterion 7

  4. Human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis C infection.

    Exclusion criterion 4

    History of malignancy within 3 years before transplantation, except adequately treated basal cell carcinoma or carcinoma in situ of the cervix.

    Exclusion criterion 6

  5. Pregnancy or breastfeeding.

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07885982, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Diagnosis of severe aplastic anemia (SAA) according to the Camitta criteria, transfusion-dependent non-severe aplastic anemia (TD-NSAA), or inherited bone marrow failure syndrome (IBMFS) with an indication for allogeneic hematopoietic stem cell transplantation (HSCT).
  • Age 1 to 50 years, regardless of sex.
  • No available HLA-matched sibling donor or 10/10 HLA-matched unrelated donor.
  • Eligible for single-unit unrelated umbilical cord blood transplantation (UCBT) using a cord blood unit that meets the protocol-defined HLA matching and minimum cell dose requirements.
  • Negative donor-specific anti-HLA antibodies (DSA) against the selected cord blood unit before transplantation.
  • Adequate cardiac, hepatic, renal, and pulmonary function.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score 0-2.
  • Serum ferritin <1000 μg/L, or prior iron chelation therapy if serum ferritin exceeds this threshold.
  • Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during treatment and for 12 months after transplantation.
  • Ability to understand the study requirements and provision of written informed consent by the participant or the participant's legally authorized representative.

Exclusion Criteria:

  • Diagnosis of myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), or other hematologic disorders causing pancytopenia.
  • Previous allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.
  • Active, uncontrolled bacterial, viral, or fungal infection despite appropriate antimicrobial therapy.
  • Human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis C infection.
  • Pregnancy or breastfeeding.
  • History of malignancy within 3 years before transplantation, except adequately treated basal cell carcinoma or carcinoma in situ of the cervix.
  • Treatment with rabbit antithymocyte globulin (rATG) within 2 weeks before transplantation.
  • Known hypersensitivity to rabbit antithymocyte globulin (rATG).
  • Active substance abuse, uncontrolled psychiatric illness, cognitive impairment, or any condition that may interfere with study participation or protocol compliance.
  • Participation in another interventional clinical trial within 3 months before enrollment.
  • Any medical, psychological, or social condition that, in the opinion of the investigator, would make the participant unsuitable for the study or interfere with study participation or follow-up.

Quoted from ClinicalTrials.gov, NCT07885982, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07885982, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07885982